Drug Trial Radar · NCT06717347
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,046
Planned (sponsor's estimate)
Start
Jan 27, 2025
Primary completion
Jul 2, 2029
Study completion Mar 29, 2032
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Dec 5, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate if zilovertamab vedotin with standard treatment can help people live longer without the cancer growing or spreading than people who receive standard treatment alone.
Conditions
- Diffuse Large B-Cell Lymphoma
Interventions
Zilovertamab vedotinBiological
IV infusion
RituximabBiological
IV infusion
CyclophosphamideDrug
IV infusion
DoxorubicinDrug
IV infusion
Rituximab BiosimilarBiological
IV infusion
PrednisoneDrug
Per Approved Product Label
PrednisoloneDrug
Oral administration
VincristineDrug
IV infusion
Rescue medicationDrug
Participants receive rescue medication per approved product label. The rescue medication is granulocyte colony-stimulating factor (G-CSF).
MethylprednisoloneDrug
Per Approved Product Label
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free survival (PFS)Time frame: Up to ~ 50 months
Locations
289 sites in 35 countries. Site status is shown where the registry gives one.
USA Mitchell Cancer Institute ( Site 0173)
Mobile, Alabama · Recruiting
Banner MD Anderson Cancer Center ( Site 0165)
Gilbert, Arizona · Recruiting
Banner MD Anderson Cancer Center - University Medical Center Phoenix ( Site 0167)
Phoenix, Arizona · Recruiting
The University of Arizona Cancer Center - North Campus ( Site 0124)
Tucson, Arizona · Recruiting
Providence Medical Foundation-Oncology ( Site 0168)
Fullerton, California · Recruiting
MemorialCare Health System - Long Beach Medical Center ( Site 9559)
Long Beach, California · Recruiting
Cancer Blood and Specialty Clinic ( Site 0109)
Los Alamitos, California · Recruiting
Cedars-Sinai Medical Center ( Site 0115)
Los Angeles, California · Recruiting
Pacific Hematology Oncology Associates ( Site 0131)
San Francisco, California · Recruiting
Lutheran Hospital - Cancer Centers of Colorado ( Site 0180)
Golden, Colorado · Recruiting
Clermont Oncology Center ( Site 0182)
Clermont, Florida · Recruiting
Bioresearch Partner ( Site 0157)
Hialeah, Florida · Recruiting
Orlando Health Cancer Institute ( Site 0169)
Ocoee, Florida · Recruiting
Mid Florida Hematology and Oncology Center ( Site 0172)
Orange City, Florida · Recruiting
Tampa General Hospital ( Site 0134)
Tampa, Florida · Recruiting
University Cancer & Blood Center, LLC ( Site 0141)
Athens, Georgia · Recruiting
Hope and Healing Cancer Services ( Site 9511)
Hinsdale, Illinois · Recruiting
Edward Cancer Center ( Site 0197)
Naperville, Illinois · Recruiting
Cancer Care Specialists of Illinois ( Site 0152)
O'Fallon, Illinois · Recruiting
Fort Wayne Medical Oncology and Hematology ( Site 0149)
Fort Wayne, Indiana · Recruiting
Cotton O'Neil Cancer Center ( Site 0108)
Topeka, Kansas · Completed
University of Kentucky ( Site 0106)
Lexington, Kentucky · Recruiting
Norton Women's and Children's Hospital-Norton Cancer Institute - St. Matthews ( Site 0163)
Louisville, Kentucky · Recruiting
Owensboro Medical Health System ( Site 0195)
Owensboro, Kentucky · Recruiting
CHRISTUS St. Frances Cabrini Hospital Center for Cancer Care ( Site 0184)
Alexandria, Louisiana · Recruiting
American Oncology Partners, P.A. ( Site 0185)
Bethesda, Maryland · Recruiting
Maryland Oncology Hematology (MOH) ( Site 8004)
Columbia, Maryland · Recruiting
Trinity Health Saint Joseph Mercy Hospital Ann Arbor ( Site 9545)
Ann Arbor, Michigan · Recruiting
Karmanos Cancer Institute ( Site 0174)
Detroit, Michigan · Recruiting
Corewell Health ( Site 0130)
Grand Rapids, Michigan · Recruiting
Central Michigan University - Saginaw ( Site 0198)
Saginaw, Michigan · Recruiting
The University of Mississippi Medical Center ( Site 0161)
Jackson, Mississippi · Recruiting
Circuit Clinical - SSM Health Cancer Care DePaul ( Site 0166)
Bridgeton, Missouri · Recruiting
University of Missouri Hospital ( Site 0175)
Columbia, Missouri · Recruiting
Truman Medical Center ( Site 0122)
Kansas City, Missouri · Recruiting
Oncology and Hematology Associates ( Site 9546)
Springfield, Missouri · Recruiting
Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana ( Site 0178)
Billings, Montana · Recruiting
OptumCare Cancer Care ( Site 0121)
Las Vegas, Nevada · Recruiting
Comprehensive Cancer Centers of Nevada ( Site 0113)
Las Vegas, Nevada · Recruiting
Cancer Care Specialists ( Site 9582)
Reno, Nevada · Recruiting
Showing 40 of 289 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.